SomaLogic Inc. is now offering increased availability to its proteomic technology with the launch of SomaSciences in the United Kingdom. The company’s proprietary SOMAscan proteomic assay offers a “one-stop shop” for validating protein biomarkers, from discovery to the validation of a companion diagnostic. SOMAscan provides protein biomarker support for drug discovery and development, from target discovery and validation and mechanism of action to efficacy predictions, patient stratification and drug response monitoring.

 

SomaLogic Inc.

(303) 625-9000

www.somalogic.com